2,500 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by nVerses Capital LLC

nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Arizona State Retirement System increased its holdings in shares of Catalyst Pharmaceuticals by 2.2% during the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 654 shares in the last quarter. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Catalyst Pharmaceuticals by 6.9% in the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 720 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 773 shares in the last quarter. Finally, Strategic Advocates LLC grew its holdings in shares of Catalyst Pharmaceuticals by 6.5% during the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 864 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Citigroup increased their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright boosted their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $29.50.

Insider Buying and Selling

In related news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 201,058 shares of company stock valued at $4,018,188 in the last ninety days. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Trading Down 1.0 %

Shares of Catalyst Pharmaceuticals stock opened at $21.02 on Tuesday. The firm has a market cap of $2.48 billion, a PE ratio of 38.93, a PEG ratio of 3.18 and a beta of 0.76. The stock has a 50 day moving average of $20.23 and a 200 day moving average of $17.46. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.89 and a 12 month high of $21.85.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The firm had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. As a group, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.